Prostate cancer is the second most common cancer in men, but the nature of the tumors – and therefore the course of treatment – can vary widely. Some prostate cancers grow and spread quickly and need aggressive treatment, while others grow and spread so slowly that it can take years for symptoms to develop. The more accurately you understand the nature of your cancer, the better equipped you are to choose the right treatment.
The prostate-specific antigen (PSA) test is currently used to diagnose prostate cancer, but it doesn’t give any information about how aggressive the cancer is. As a result, men often must undergo additional, more invasive tests, including digital rectal exams and biopsies, to determine treatment course.
ExoDx Prostate(IntelliScore), available now, is a non-invasive urine test that accurately predicts the aggressiveness of prostate cancer. Our test will provide you and your doctor with the information necessary to determine the best course of action for treating your cancer.
About the Test
What is ExoDx Prostate(IntelliScore)?
ExoDx Prostate(IntelliScore) is a simple urine test that detects three important genetic biomarkers that can identify the aggressiveness of prostate cancer. Using this assessment, your physician can determine whether or not you should undergo an initial biopsy or continue to be monitored for disease progression. Treatment for prostate cancer can have unpleasant and disruptive side effects like impotence and incontinence, so for many men with slow-growing tumors, active surveillance may be a better choice.
- Detects three important genetic biomarkers that can identify aggressive prostate cancer.
- Non-invasive test that does not require a digital rectal exam.
- Provides physicians with an easy-to-read score that corresponds to the Gleason Score. The Gleason Score is the measure used to grade cancer cells in biopsied tissue.
- Shown to accurately identify the presence of aggressive prostate cancer in a large, multi-center trial.
How Does the Test Work?
If your PSA result suggests that you might have prostate cancer, your doctor will be able to use our liquid biopsy test to look for three genetic biomarkers that appear in the urine of men with high-grade or aggressive prostate cancer. It’s a simple, non-invasive urine test, so you don’t have to undergo a digital rectal exam or premature surgical biopsy.
If the results of your test indicate that you do have high-grade prostate cancer, your doctor will talk to you about your treatment options. You may need additional tests to determine the extent of the cancer and its stage. If the results do not indicate the presence of a high-grade tumor, your physician may discuss the possibility of active surveillance rather than a tissue biopsy.
How Can I Get the Test?
EPI is a Laboratory Developed Test (LDT) offerec from our CLIA certified lab. A physician's office can order the test on line here or call 844 EXOSOME (844 396 7663)
About Prostate Cancer
Prostate cancer is the second most common cancer in men after skin cancer, and more than a quarter of a million men will be diagnosed with prostate cancer this year in the U.S. Risk factors include age, race and family history of prostate cancer.
The prostate is a walnut-sized gland that produces the fluid that carries sperm cells and is located below the bladder and in front of the rectum. Nearly all prostate cancers begin in the gland cells that make prostate fluid. This is called an adenocarcinoma. Some prostate cancers can grow and spread quickly, but most grow very slowly. In fact, most men are likely to die of other causes before becoming symptomatic.
Early prostate cancer is generally asymptomatic while advanced prostate cancer can cause frequent urination, the feeling that the urethra is blocked and blood in the semen. However, it is important to remember that some of these symptoms also occur with benign enlargement of the prostate. If you do experience these symptoms please consult your doctor.
Resources for Patients
Learn More About Prostate Cancer
National Cancer Institute
Find fact sheets and publications on prostate cancer and its prevention, screening and treatment as well as patient resources and access to clinical trials.
American Cancer Society
Get information about prostate cancer statistics, screening, symptoms and treatment. National and local affiliates support research and policy, and provide accurate information about cancer prevention and treatment, support groups, survivorship care plans and other tools.
Prostate Cancer Information and Support Services
Prostate Cancer Foundation (formerly CaPCURE)
Provides information on prostate cancer and treatment options as well as patient guides and survivor stories.
US Too International, Inc.
Offers information about all stages of prostate cancer, different treatment options, new research findings and current clinical trials, and some referrals to local support groups.
General Cancer Information and Support Services
National Cancer Institute Cancer Information Service
Live help line provides accurate, up-to-date information about cancer to patients, their families and the general public; also helps people find clinical trials in their area.
National Coalition for Cancer Survivorship
1-877-622-7937 (1-877-NCCS-YES) for publications and Cancer Survivor Toolbox® orders
Offers information on work, health insurance and more. The Cancer Survival Toolbox is a free, self-learning audio program to help cancer survivors and caregivers develop practical skills needed to deal with the diagnosis, treatment and challenges of cancer. Listen online or order CDs. Also available in Spanish and Chinese.
Patient Advocate Foundation
Provides patients with debilitating diseases with arbitration, mediation and negotiation services to settle issues with access to care, medical debt and insurance.
Searchable database that provides patients, family members and the public with information about current ongoing clinical research studies.
Questions from healthcare providers or patients can be directed to our main number at 844 EXOSOME (844 396 7663)